DE60328201D1 - Impstoff gegen yersinia mit einem oder zwei monoklonaler antikörper, die für yersinia pestis f1-antigen und v-antigen spezifisch sind - Google Patents

Impstoff gegen yersinia mit einem oder zwei monoklonaler antikörper, die für yersinia pestis f1-antigen und v-antigen spezifisch sind

Info

Publication number
DE60328201D1
DE60328201D1 DE60328201T DE60328201T DE60328201D1 DE 60328201 D1 DE60328201 D1 DE 60328201D1 DE 60328201 T DE60328201 T DE 60328201T DE 60328201 T DE60328201 T DE 60328201T DE 60328201 D1 DE60328201 D1 DE 60328201D1
Authority
DE
Germany
Prior art keywords
antigen
yersinia
yersinia pestis
monoclonal antibodies
antibodies specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60328201T
Other languages
English (en)
Inventor
James Hill
Ethel Diane Williamson
Richard William Titball
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of DE60328201D1 publication Critical patent/DE60328201D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE60328201T 2002-08-31 2003-08-29 Impstoff gegen yersinia mit einem oder zwei monoklonaler antikörper, die für yersinia pestis f1-antigen und v-antigen spezifisch sind Expired - Fee Related DE60328201D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220257.0A GB0220257D0 (en) 2002-08-31 2002-08-31 Vaccine
PCT/GB2003/003747 WO2004019980A1 (en) 2002-08-31 2003-08-29 Vaccine against yersinia comprising one or two antibodies, one specific for yersinia pestis f1-antigen and the other one for yersina pestis v-antigen

Publications (1)

Publication Number Publication Date
DE60328201D1 true DE60328201D1 (de) 2009-08-13

Family

ID=9943275

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60328201T Expired - Fee Related DE60328201D1 (de) 2002-08-31 2003-08-29 Impstoff gegen yersinia mit einem oder zwei monoklonaler antikörper, die für yersinia pestis f1-antigen und v-antigen spezifisch sind

Country Status (9)

Country Link
US (1) US7572449B2 (de)
EP (1) EP1536833B1 (de)
JP (1) JP2006500386A (de)
AT (1) ATE435032T1 (de)
AU (1) AU2003260752A1 (de)
CA (1) CA2495833A1 (de)
DE (1) DE60328201D1 (de)
GB (1) GB0220257D0 (de)
WO (1) WO2004019980A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343170A (zh) * 2023-10-13 2024-01-05 青海省地方病预防控制所 用于检测鼠疫耶尔森菌的抗LcrV抗体及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101337069B (zh) * 2005-11-25 2012-07-25 中国药品生物制品检定所 复合鼠疫疫苗及其制备方法
GB0525213D0 (en) * 2005-12-12 2006-01-18 Secr Defence Vaccine
US7815911B1 (en) * 2006-10-10 2010-10-19 University Of Kentucky Research Foundation Compositions and methods for treating Yersinia pestis infection
WO2010043046A1 (en) * 2008-10-16 2010-04-22 Mcmaster University Peptide inhibitors of type iii secretion
WO2010117455A2 (en) * 2009-04-08 2010-10-14 U.S. Army Medical Research Institute Of Infectious Diseases Human monoclonal antibodies protective against bubonic plaque

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326425D0 (en) 1993-12-24 1994-02-23 Secr Defence Vaccine compositions
EP0815235B1 (de) 1995-03-13 2003-01-15 The Secretary of State for Defence Impfstoffe gegen die pest
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU5046700A (en) * 1999-05-28 2000-12-18 Jennifer Aldrich Diagnostic monoclonal antibody for LTiGTyersinia pestisLT/iGT
US20050181063A1 (en) 2000-03-22 2005-08-18 Alpar Hazire O. Pharmaceutical composition for administration to mucosal surfaces

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343170A (zh) * 2023-10-13 2024-01-05 青海省地方病预防控制所 用于检测鼠疫耶尔森菌的抗LcrV抗体及其应用
CN117343170B (zh) * 2023-10-13 2024-04-05 青海省地方病预防控制所 用于检测鼠疫耶尔森菌的抗LcrV抗体及其应用

Also Published As

Publication number Publication date
US20060093609A1 (en) 2006-05-04
WO2004019980A1 (en) 2004-03-11
JP2006500386A (ja) 2006-01-05
EP1536833A1 (de) 2005-06-08
US7572449B2 (en) 2009-08-11
AU2003260752A1 (en) 2004-03-19
CA2495833A1 (en) 2004-03-11
ATE435032T1 (de) 2009-07-15
EP1536833B1 (de) 2009-07-01
GB0220257D0 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
CY1118098T1 (el) Fc riib-ειδικα αντισωματα και μεθοδοι χρησης αυτων
WO2019178269A3 (en) Antibodies that bind cd39 and uses thereof
CL2010000788A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03).
NO20072733L (no) Doseformer
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CL2012000519A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de carcinoma de células escamosas en un mamífero (div. sol. 3615-07).
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CR11243A (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
NO20052220L (no) Fremgangsmater for behandling av Alzheimers sykdom ved anvendelse av antistoffer rettet mot amyloid beta-peptid og preparater derav
WO2005115452A3 (en) Fcϝriib-specific antibodies and methods of use thereof
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
ATE528319T1 (de) Krebsbehandlung mit anti-il-1-antikörpern
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
MX2021004173A (es) Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
WO2018027124A8 (en) ANTI-O2 ANTIBODIES AND USES THEREOF
ATE364396T1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
WO2020023644A3 (en) Antibody directed against s. aureus clumping factor a (clfa)
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee